021-51111890
购物车（）
sales@molnova.cn
Motesanib
CAS No. 453562-69-1
Motesanib ( AMG 706; AMG-706 )
产品货号. M14539 CAS No. 453562-69-1
A potent, orally bioavailable, multikinase inhibitor inhibitor of VEGFR1/2/3, PDGFR and c-Kit with IC50 of 2-6 nM, 84 nM and 8 nM, respectively.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥300 | 有现货 |
|
| 10MG | ￥437 | 有现货 |
|
| 50MG | ￥1409 | 有现货 |
|
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Motesanib
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述A potent, orally bioavailable, multikinase inhibitor inhibitor of VEGFR1/2/3, PDGFR and c-Kit with IC50 of 2-6 nM, 84 nM and 8 nM, respectively.
-
产品描述A potent, orally bioavailable, multikinase inhibitor inhibitor of VEGFR1/2/3, PDGFR and c-Kit with IC50 of 2-6 nM, 84 nM and 8 nM, respectively; also displays activity against Ret (IC50=59 nM), no activities against EGFR, Src, and p38; inhibits human endothelial cell proliferation induced by VEGF, but not by bFGF in vitro; potently inhibits VEGF-induced angiogenesis in the rat models.Lung Cancer Phase 3 Discontinued
-
同义词AMG 706; AMG-706
-
通路Angiogenesis
-
靶点VEGFR
-
受体VEGFR1;VEGFR2;VEGFR3
-
研究领域Cancer
-
适应症Lung Cancer
化学信息
-
CAS Number453562-69-1
-
分子量373.45
-
分子式C22H23N5O
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 30 mg/mL
-
SMILESCC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C
-
化学全称3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Polverino A, et al. Cancer Res. 2006 Sep 1;66(17):8715-21.
2. Sherman SI, et al. N Engl J Med. 2008 Jul 3;359(1):31-42.
3. Coxon A, et al. lin Cancer Res. 2009 Jan 1;15(1):110-8.
4. Caenepeel S, et al. J Exp Clin Cancer Res. 2010 Jul 15;29:96.
2. Sherman SI, et al. N Engl J Med. 2008 Jul 3;359(1):31-42.
3. Coxon A, et al. lin Cancer Res. 2009 Jan 1;15(1):110-8.
4. Caenepeel S, et al. J Exp Clin Cancer Res. 2010 Jul 15;29:96.
产品手册
关联产品
-
Vatalanib free base
A potent, orally available class III receptor tyrosine kinases inhibitor with IC50 of <1 uM for VEGFR, Flt-1, KDR and PDGFRβ.
-
Ramucirumab
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors.
-
WAY-302159
WAY-302159 is a VEGFR2 inhibitor.
